title: Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
authors.affiliation: West German Cancer Center, University of Essen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Richly
authors.forename: P
authors.initials: P
authors.lastname: Kupsch
authors.forename: K
authors.initials: K
authors.lastname: Passage
authors.forename: M
authors.initials: M
authors.lastname: Grubert
authors.forename: R A
authors.initials: RA
authors.lastname: Hilger
authors.forename: R
authors.initials: R
authors.lastname: Voigtmann
authors.forename: B
authors.initials: B
authors.lastname: Schwartz
authors.forename: E
authors.initials: E
authors.lastname: Brendel
authors.forename: O
authors.initials: O
authors.lastname: Christensen
authors.forename: C G
authors.initials: CG
authors.lastname: Haase
authors.forename: D
authors.initials: D
authors.lastname: Strumberg
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019540:Area Under Curve; D001557:Benzenesulfonates / Q000009:adverse effects / Q000627:therapeutic use*; D018281:Cholangiocarcinoma / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D004317:Doxorubicin; D000077157:Sorafenib